Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us

Invokana Lawsuit

The FDA has cautioned patients to be aware of the potential link between Invokana and diabetic ketoacidosis – a condition of high levels of acid accumulating in the blood.

In 2013, Johnson & Johnson introduced the diabetes drug Invokana to the market. Invokana was the first member of a new class of diabetes drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors – a drug designed to work by inhibiting some kidney functions to increase the amount of sugar excreted in urine.

A little more than two years after Invokana’s introduction to the market, the U.S. Food and Drug Administration (“FDA”) issued a warning about serious risks associated with Invokana and other similar SGLT2 inhibitors. The FDA, in its May 2015 report, highlighted more than 20 adverse event reports linked to SGLT2 inhibitors, each of which resulted in hospitalization or emergency room treatment.

Problems associated with Invokana include kidney failure, kidney impairment, kidney stones, urinary tract infections, and abnormal weight loss. The FDA has cautioned patients to be aware of the potential link between Invokana and diabetic ketoacidosis – a condition of high levels of acid accumulating in the blood. Difficulty breathing, nausea or vomiting, abdominal pain, confusion, fatigue and sleeplessness are all symptoms of ketoacidosis.

Wexler Wallace is currently representing individuals who are or have taken Invokana and experienced complications or side effects from taking the drug. If you or a loved one has suffered from diabetic ketoacidosis or experienced any adverse symptoms from taking Invokana, please contact us to speak to an attorney about your potential claim.

We maintain the confidentiality of all inquiries and information provided.

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP